Moreover, Entrectinib, a potent CNS-penetrant inhibitor of TRKA/B/C, ROS1 and ALK, was also evaluated to treat children and young adults with solid or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations [730]. Here, ALK is linked to central nervous system neoplasm.